3262 related articles for article (PubMed ID: 12407406)
1. Cancer immunoediting: from immunosurveillance to tumor escape.
Dunn GP; Bruce AT; Ikeda H; Old LJ; Schreiber RD
Nat Immunol; 2002 Nov; 3(11):991-8. PubMed ID: 12407406
[TBL] [Abstract][Full Text] [Related]
2. The immunobiology of cancer immunosurveillance and immunoediting.
Dunn GP; Old LJ; Schreiber RD
Immunity; 2004 Aug; 21(2):137-48. PubMed ID: 15308095
[TBL] [Abstract][Full Text] [Related]
3. Tumor immunoediting and immunosculpting pathways to cancer progression.
Reiman JM; Kmieciak M; Manjili MH; Knutson KL
Semin Cancer Biol; 2007 Aug; 17(4):275-87. PubMed ID: 17662614
[TBL] [Abstract][Full Text] [Related]
4. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.
Schreiber RD; Old LJ; Smyth MJ
Science; 2011 Mar; 331(6024):1565-70. PubMed ID: 21436444
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy.
Vesely MD; Schreiber RD
Ann N Y Acad Sci; 2013 May; 1284(1):1-5. PubMed ID: 23651186
[TBL] [Abstract][Full Text] [Related]
6. The three Es of cancer immunoediting.
Dunn GP; Old LJ; Schreiber RD
Annu Rev Immunol; 2004; 22():329-60. PubMed ID: 15032581
[TBL] [Abstract][Full Text] [Related]
7. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.
Matsushita H; Vesely MD; Koboldt DC; Rickert CG; Uppaluri R; Magrini VJ; Arthur CD; White JM; Chen YS; Shea LK; Hundal J; Wendl MC; Demeter R; Wylie T; Allison JP; Smyth MJ; Old LJ; Mardis ER; Schreiber RD
Nature; 2012 Feb; 482(7385):400-4. PubMed ID: 22318521
[TBL] [Abstract][Full Text] [Related]
8. [Immune system and tumors].
Terme M; Tanchot C
Ann Pathol; 2017 Feb; 37(1):11-17. PubMed ID: 28159405
[TBL] [Abstract][Full Text] [Related]
9. Interferon-gamma and cancer immunoediting.
Dunn GP; Ikeda H; Bruce AT; Koebel C; Uppaluri R; Bui J; Chan R; Diamond M; White JM; Sheehan KC; Schreiber RD
Immunol Res; 2005; 32(1-3):231-45. PubMed ID: 16106075
[TBL] [Abstract][Full Text] [Related]
10. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.
Algarra I; García-Lora A; Cabrera T; Ruiz-Cabello F; Garrido F
Cancer Immunol Immunother; 2004 Oct; 53(10):904-10. PubMed ID: 15069585
[TBL] [Abstract][Full Text] [Related]
11. [The relationship between immunological defence and the development of tumours].
Leone G
Arch Sci Med (Torino); 1973; 130(4):273-82. PubMed ID: 17343168
[TBL] [Abstract][Full Text] [Related]
12. Expression of tumour-specific antigens underlies cancer immunoediting.
DuPage M; Mazumdar C; Schmidt LM; Cheung AF; Jacks T
Nature; 2012 Feb; 482(7385):405-9. PubMed ID: 22318517
[TBL] [Abstract][Full Text] [Related]
13. Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens.
Tveita AA; Schjesvold F; Haabeth OA; Fauskanger M; Bogen B
Cancer Res; 2015 Aug; 75(16):3268-78. PubMed ID: 26038231
[TBL] [Abstract][Full Text] [Related]
14. The immune system--is it relevant to cancer development, progression and treatment?
Prestwich RJ; Errington F; Hatfield P; Merrick AE; Ilett EJ; Selby PJ; Melcher AA
Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):101-12. PubMed ID: 18037277
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunosurveillance and immunoediting by natural killer cells.
Gross E; Sunwoo JB; Bui JD
Cancer J; 2013; 19(6):483-9. PubMed ID: 24270347
[TBL] [Abstract][Full Text] [Related]
16. Natural selection of tumor variants in the generation of "tumor escape" phenotypes.
Khong HT; Restifo NP
Nat Immunol; 2002 Nov; 3(11):999-1005. PubMed ID: 12407407
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic escape of immunosurveillance by malignant cell precursors.
Galassi C; Galluzzi L
EMBO J; 2023 May; 42(10):e114050. PubMed ID: 37051718
[TBL] [Abstract][Full Text] [Related]
18. Challenges and prospects of immunotherapy as cancer treatment.
Rescigno M; Avogadri F; Curigliano G
Biochim Biophys Acta; 2007 Sep; 1776(1):108-23. PubMed ID: 17720322
[TBL] [Abstract][Full Text] [Related]
19. The concept of immune surveillance against tumors. The first theories.
Ribatti D
Oncotarget; 2017 Jan; 8(4):7175-7180. PubMed ID: 27764780
[TBL] [Abstract][Full Text] [Related]
20. Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.
Wilczyński JR; Nowak M
Exp Suppl; 2022; 113():1-57. PubMed ID: 35165859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
